Call for urgent action on energy drinks as new UK research reveals daily use among young people

A consistent number of young people are having energy drinks daily, despite an overall drop in the consumption of sugary beverages over time, new research has found. Academics at Cardiff University analyzed the responses of more than 176,000 secondary school children aged 11 to 16. They found between 2013 to 2017, when their use began to be recorded, the proportion […]

Read more

Classification scheme developed for newly identified multiple sclerosis-like disease

Researchers in the Department of Neurology at Tohoku University, which is led by professor Masashi Aoki, have developed a classification scheme for neuromyelitis optica spectrum disorder, a rare autoimmune disease that until recently was thought to be a type of multiple sclerosis (MS). The new taxonomy for the disease replaces one borrowed from MS but which was inappropriate for what […]

Read more

Major risk of injury for recreational runners

Almost half of all recreational runners incur injuries, mostly relating to knees, calves or Achilles tendons, and the level of risk is equally high whatever your age, gender or running experience. These are the findings of a thesis within sport science. Doctoral student Jonatan Jungmalm recruited a little over 200 recreational runners from the list of entrants for the Göteborgsvarvet […]

Read more

FDA Approves Trodelvy, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

FOSTER CITY, Calif.–(BUSINESS WIRE)–Apr. 7, 2021– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Trodelvy® (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. The approval is supported by data […]

Read more

Another promising approach for hard-to-treat blood cancers

For patients with some hard-to-treat blood cancers, a simple “off-the-shelf” immunotherapy is achieving promising results. A clinical trial of the developmental drug Glofitamab has shown it can produce a durable “complete response”—meaning the cancer became undetectable—in patients with relapsed or treatment resistant B-cell lymphomas. One option for these patients is CAR T-cell therapy—also an immunotherapy but one which involves collecting […]

Read more

Another promising approach for hard-to-treat blood cancers

For patients with some hard-to-treat blood cancers, a simple “off-the-shelf” immunotherapy is achieving promising results. A clinical trial of the developmental drug Glofitamab has shown it can produce a durable “complete response”—meaning the cancer became undetectable—in patients with relapsed or treatment resistant B-cell lymphomas. One option for these patients is CAR T-cell therapy—also an immunotherapy but one which involves collecting […]

Read more

With a big if, EU hopes for ‘community immunity’ by June

Despite its flagging vaccination drive, the European Union said Tuesday it is still on target to reach what it calls “sufficient community immunity” by the end of June. The European Commission has said it wants to have vaccinated a minimum 70% of the entire adult population by the end of the summer. But it is counting on a strong second […]

Read more
1 2 3 56